- EirGenix has entered into a second global exclusive licensing agreement with Sandoz for the commercialisation of its breast cancer biosimilar EG1206A.
- The deal includes up to USD 152 million in upfront and milestone payments, alongside profit sharing and potential sales incentives.
EirGenix Inc. has signed a second global exclusive licensing agreement with Sandoz AG for the commercialisation of EG1206A, its independently developed pertuzumab biosimilar to Roche’s Perjeta®. The agreement covers all territories except a set of Asian markets, and strengthens the companies’ collaboration on HER2-targeted biosimilars.
Under the agreement, EirGenix will receive up to USD 152 million in upfront and milestone payments. The company will also be entitled to a profit share once the product is launched in licensed territories, as well as potential sales-based incentives. EirGenix will handle product development, manufacturing, and supply.
EG1206A has completed its pharmacokinetic clinical study and recently received positive feedback from both the U.S. FDA and the European Medicines Agency, confirming eligibility for an abbreviated development pathway without Phase III comparative efficacy trials. The partnership builds on an earlier global agreement covering the trastuzumab biosimilar EG12014, which has been approved by the European Commission and is under review by the U.S. FDA.
EirGenix states that the deal reflects its technical capabilities and growing international footprint. The company is advancing four HER2-targeted antibody programmes and expanding both its internal pipeline and CDMO services. Its production facilities in Zhubei continue to attract international partners as biosimilar development and manufacturing demand accelerates.
